Results 241 to 250 of about 325,231 (306)

Altered Protein Structures and Neoepitopes in Lupus Neutrophils From Dysregulated Splicing of Messenger RNA. [PDF]

ACR Open Rheumatol
Najjar R, Wang X, Pineda JMB, Alessi H, Bays A, Bradley RK, Jarvis JN, Mustelin T.   +7 more
europepmc   +1 more source

Viscosity of concentrated mRNA solutions: Implications for downstream processing

Biotechnology Progress, EarlyView.
Abstract Messenger RNA (mRNA) therapeutics can be used to protect against infectious disease and for the treatment of cancers and genetic disorders. In order to obtain the desired therapeutic dosage, it is necessary to concentrate the mRNA to levels where the viscosity of the mRNA solutions can become significant.
Amin Javidanbardan, Fatemeh Najafi, Ziqiao Wang, Andrew L. Zydney   +3 more
wiley   +1 more source

Immunoinformatic development of a multiepitope messenger RNA vaccine targeting lipoate protein ligase and dihydrolipoamide dehydrogenase proteins of <i>Mycoplasma bovis</i> in cattle. [PDF]

Vet World
Al-Fetly DR, Alsallami D, Alsultan A.
europepmc   +1 more source

PERFECTA Loaded Lipid Cubosomes for 19F‐MRI: Physico‐Chemical Characterization

Chemistry – A European Journal, EarlyView.
Phytantriol‐based cubosomes loaded with PERFCTA, a fluorinated MRI probe, were developed as promising systems for imaging and drug delivery. The nanoparticles showed high PERFECTA encapsulation efficiency, strong fluorine MRI signals, and optimal colloidal stability in biological media.
Pietro Milesi, Beatrice Lucia Bona, Cristina Chirizzi, Marco Campanile, Pompea Del Vecchio, Marc Schmutz, Valerie Sartor, Debora Berti, Pierangelo Metrangolo, Francesca Baldelli Bombelli, Barbara Lonetti   +10 more
wiley   +1 more source

Resolving the Structure of a Guanine Quadruplex in TMPRSS2 Messenger RNA by Circular Dichroism and Molecular Modeling. [PDF]

Chemistry
D'Anna L, Froux A, Rainot A, Spinello A, Perricone U, Barbault F, Grandemange S, Barone G, Terenzi A, Monari A.   +9 more
europepmc   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

The effect of sleep and shift work on the primary immune response to messenger RNA-based COVID-19 vaccination. [PDF]

J Sleep Res
Brouwers TMJ, Çobanoğlu ÜG, Geers D, Rietdijk WJR, Gommers L, Bogers S, Lammers GJ, van der Horst GTJ, Chaves I, GeurtsvanKessel CH, Koch BCP, de Vries RD, van Baarle D, van der Kuy HM, Lammers-van der Holst HM.   +14 more
europepmc   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

A Case of Rapid Transformation of a Nail Matrix Nevi to Melanoma After Messenger RNA COVID-19 Vaccine: A Cause or a Coincidence? [PDF]

Cureus
Farhat M, Zouein J, Abou Khater J, Sarkis AS, Helou J.   +4 more
europepmc   +1 more source

Lipid‐based Nano‐delivery systems as a promising strategy for the treatment of epilepsy: Current status and challenges

Epilepsia Open, EarlyView.
Abstract Objective Epilepsy is a prevalent chronic neurological disorder characterized by abnormal neuronal electrical activity. The primary treatment modality for individuals with epilepsy (PWE) is antiseizure medication (ASM). The multiple potential factors contributing to treatment resistance in epilepsy may be attributed to the inability of ASMs to
Priya Kannan Varshini, Arunachalam Divya, Kumar Sowndharya, Parthiban Jeevitha, Selvam Manoj, Ashiq Rahman, Athil Ahamed, Ravichandiran Abirahul, Paranthaman Subash, Sulekha Khute   +9 more
wiley   +1 more source